Vivoryon Therapeutics Liabilities 2024

Vivoryon Therapeutics Aktienanalyse

What does Vivoryon Therapeutics do?

Vivoryon Therapeutics NV is a biopharmaceutical company specializing in the development of drugs for the treatment of Alzheimer's and other neurodegenerative diseases. The company was founded in 2016 in Leuven, Belgium and is headquartered in Heidelberg, Germany. Vivoryon Therapeutics has a history dating back to 2005 when it was supported by EFPIA-AIM. The company has since gone through several successful financing rounds to advance its research and development efforts. Its business model is based on the discovery and development of therapeutics with a new chemical approach to treating Alzheimer's and other neurodegenerative diseases. Vivoryon Therapeutics is currently involved in three different therapy areas: small molecule blockers, epigenetics, and big data analytics and telemetry technologies. The company is also developing a drug known as PQ912, which has the potential to slow down the progression of Alzheimer's disease. Vivoryon Therapeutics has partnerships and collaborations with various institutions to further its research and development programs. Overall, the company has the potential to revolutionize the treatment of Alzheimer's and other neurodegenerative diseases through its innovative efforts and collaborations. Vivoryon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Vivoryon Therapeutics's Liabilities

Vivoryon Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vivoryon Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Vivoryon Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Vivoryon Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Vivoryon Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Vivoryon Therapeutics stock

What is the level of liabilities of Vivoryon Therapeutics this year?

Vivoryon Therapeutics has a debt balance of 4.55 M EUR this year.

What were the liabilities of Vivoryon Therapeutics compared to the previous year?

The liabilities of Vivoryon Therapeutics have increased by -6.67% dropped compared to the previous year.

What are the consequences of high debt for investors of Vivoryon Therapeutics?

High liabilities can pose a risk for investors of Vivoryon Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Vivoryon Therapeutics?

Low liabilities mean that Vivoryon Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Vivoryon Therapeutics affect the company?

An increase in liabilities of Vivoryon Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Vivoryon Therapeutics affect the company?

A decrease in the liabilities of Vivoryon Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Vivoryon Therapeutics?

Some factors that can influence the liabilities of Vivoryon Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Vivoryon Therapeutics so important for investors?

The liabilities of Vivoryon Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Vivoryon Therapeutics take to modify the liabilities?

To change its liabilities, Vivoryon Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Vivoryon Therapeutics pay?

Over the past 12 months, Vivoryon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vivoryon Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Vivoryon Therapeutics?

The current dividend yield of Vivoryon Therapeutics is .

When does Vivoryon Therapeutics pay dividends?

Vivoryon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vivoryon Therapeutics?

Vivoryon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Vivoryon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vivoryon Therapeutics located?

Vivoryon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vivoryon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vivoryon Therapeutics from 10/3/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Vivoryon Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Vivoryon Therapeutics in the year 2023?

In the year 2023, Vivoryon Therapeutics distributed 0 EUR as dividends.

In which currency does Vivoryon Therapeutics pay out the dividend?

The dividends of Vivoryon Therapeutics are distributed in EUR.